LETTER TO THE EDITOR

Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia

Juan Feng1,2†, Yan Li1†, Yujiao Jia1, Qiuyun Fang1, Xiao Yuan Gong1, Xiaobao Dong1, Kun Ru1, Qinghua Li1, Xingli Zhao1, Kaiqi Liu1, Min Wang2, Zheng Tian2, Yannan Jia1,2, Ying Wang1, Dong Lin1, Hui Wei1,2, Kejing Tang2, Yingchang Mi1,2* and Jianxiang Wang1,2*

Abstract

Target-specific next-generation sequencing technology was used to analyze 112 genes in adult patients with acute lymphoblastic leukemia (ALL). This sequencing mainly focused on the specific mutational hotspots. Among the 121 patients, 93 patients were B-ALL (76.9%), and 28 patients (23.1%) were T-ALL. Of the 121 patients, 110 (90.9%) harbored at least one mutation. The five most frequently mutated genes in T-ALL are NOTCH1, JAK3, FBXW7, FAT1, and NRAS. In B-ALL, FAT1, SF1, CRLF2, TET2, and PTPN11 have higher incidence of mutations. Gene mutations are different between Ph+ALL and Ph−ALL patients. B-ALL patients with PTPN11 mutation and T-ALL patients with NOTCH1 and/or FBXW7 mutations showed better survival. But B-ALL with JAK1/JAK2 mutations showed worse survival. The results suggest that gene mutations exist in adult ALL patients universally, they are related with prognosis.

Keywords: Next-generation sequencing, Somatic mutations, Prognostic significance, Acute lymphoblastic leukemia

To the editor

Acute lymphoblastic leukemia (ALL) represents one of the most common malignant diseases of childhood, accounts for about 15 ~ 25% of acute leukemia in adults [1]. Adult ALL is generally characterized by diverse biological features, evident clinical heterogeneity, and worse prognosis than pediatric ALL [2]. With the development of genomics in ALL, several new subtypes of ALL and a series of prognostic-related molecular markers are put forward [3–5]. In the recent years, with the application of next-generation sequencing (NGS) technology, genomics has been extensively developed in both pediatric and adult ALL patients [6]. Samples and clinical information were collected from 121 adult ALL patients (Additional file 1: Table S1) with informed consent (ethical approval serial number is KT2015001-EC-1). These patients were from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Target regions of 112 genes (Additional file 2: Table S2) were selected on the basis of known or suspected involvement in the pathogenesis of malignant hematologic disorder and were enriched and analyzed using a custom targeted NGS gene panel (Additional file 3). Then, the relationships between the mutations with higher incidence and the prognosis of ALL patients were analyzed (Additional file 4). Of the 121 patients, a total of 110 patients (90.9%) harbored at least one gene mutation with a median of 2 (0–7) mutations per sample. Thirty-nine patients (32.2%) had more than 3 gene mutations (Additional file 5: Figure S1). Sixty genes were considered as possible pathogenic mutations when compared against multiple databases (Fig. 1a. The top 38 mutated genes were
The five most frequently mutated genes were FAT1, NOTCH1, SF1, CRLF2, and NRAS (mutated in >8% of the cases).

In 28 T-ALL cases, the most common mutated gene was NOTCH1, with a mutation rate of 39.3% (n = 11), then JAK3, FBXW7, FAT1, NRAS, CREBBP, DNM2 (mutated in >10% of the cases) (Additional file 6: Figure S2A). In B-ALL, FAT1 was the most accepted mutated gene (10.75%), then SF1, CRLF2, TET2, PTPN11, NRAS, CREBBP, JAK2, DIS3, MPL, and KML2D (mutated in >5% of the cases) (Additional file 6: Figure S2B). In Ph+ B-ALL, FAT1, CRLF2, SF1, EP300, and CREBBP genes mutated at higher incidences (Additional file 6: Figure S2C). However, PTPN11, SF1, TET2, NRAS, JAK2, DIS3, and FAT1 gene mutations occurred popularly in Ph B-ALL (Additional file 6: Figure S2D).

The main signaling pathways involved in this targeted NGS gene panel were transcription factor/regulator, Ras/protein phosphatase/MARK signaling pathway, JAK-STAT pathway, splicing and mRNA processing regulation, epigenetic modulators, and so on [7–9]. Frequencies of different signaling pathways involved are listed in Fig. 1b. Genes involved in these signaling pathways are listed in Additional file 7: Table S3.

In full cohort, the median overall survival (OS) was 34.88 (1.25–74.55) months, median relapse-free survival (RFS) was 30.85 (0–73.55) months and 3-year OS and RFS rates were 49%. In the full cohort, patients with PTPN11 mutation had a better prognosis compared with patients without PTPN11 mutation (p = 0.040, p = 0.047), and the patients with JAK2 mutation (7/117) had a worse prognosis compared with patients without JAK2 mutation (p = 0.031, p = 0.018) (Additional file 8: Figure S3). B-ALL patients with PTPN11 mutation (7/93) had a better OS and RFS compared with those without PTPN11 mutation (p = 0.041, p = 0.047) (Additional file 9: Figure S4).

In T-ALL, patients with NOTCH1 and/or FBXW7 mutations had a better OS and RFS than patients without these mutations (p = 0.035, p = 0.048) (Additional file 10: Figure S5).

Multivariate analysis of OS and RFS showed that the prognostic factors included JAK2 mutations (OS; p = 0.045, RFS; p = 0.021) in the total adult ALL patients cohort. JAK1 mutations (OS; p = 0.004, RFS; p = 0.005) and JAK2 mutations (OS; p = 0.049, RFS; p = 0.044) for Ph B-ALL. The data was summarized in Table 1.
In summary, our study suggests that gene mutations exist in adult ALL patients universally, involving a variety of signaling pathways. The frequency and species are varied in different types of ALL. B-ALL patients were accompanied with PTPN11 mutation for good prognosis, while abnormal JAK family often indicates poor prognosis. In T-ALL, mutation of NOTCH1 and/or FBXW7 indicates good prognosis.

Additional files

Table 1 Univariate and multivariate analysis for OS and RFS

|                      | OS          | RFS         |
|----------------------|-------------|-------------|
|                      | HR^2        | P value     | HR^2        | P value     |
| Univariate analysis  |             |             |             |             |
| PTPN11 mut; positive vs negative in full cohort (8/117) | 0.043 | 0.040 | 0.044 | 0.047 |
| In B-ALL (7/92)      | 0.042 | 0.041 | 0.042 | 0.047 |
| In Ph^B-ALL (7/54)   | 0.035 | 0.030 | 0.037 | 0.047 |
| JAK2 Mut; positive vs negative in full cohort (7/117) | 3.02 | 0.031 | 3.309 | 0.018 |
| In B-ALL (5/92)      | 3.033 | 0.061 | 3.145 | 0.051 |
| In Ph^B-ALL (5/54)   | 3.728 | 0.035 | 3.780 | 0.031 |
| JAK1 mut; positive vs negative in Ph^B-ALL (4/54) | 6.808 | 0.001 | 6.562 | 0.001 |
| NOTCH1 and/or FBXW7 mut; positive vs negative in T-ALL (12/25) | 0.204 | 0.035 | 0.223 | 0.048 |
| Multivariate analysis|             |             |             |             |
| PTPN11 mut; positive vs negative in full cohort | 0.043 | 0.052 | 0.044 | 0.056 |
| In B-ALL | 0.042 | 0.063 | 0.042 | 0.056 |
| In Ph^B-ALL | 0.035 | 0.178 | 0.037 | 0.212 |
| JAK2 mut; positive vs negative in full cohort | 3.02 | 0.045 | 3.309 | 0.021 |
| In Ph^B-ALL | 3.728 | 0.049 | 3.780 | 0.044 |
| JAK1 mut; positive vs negative in Ph^B-ALL | 6.808 | 0.004 | 6.562 | 0.005 |
| NOTCH1 and/or FBXW7 mut; positive vs negative in T-ALL | 0.204 | 0.055 | 0.223 | 0.069 |

In summary, our study suggests that gene mutations exists in adult ALL patients universally, involving a variety of signaling pathways. The frequency and species are varied in different types of ALL. B-ALL patients were accompanied with PTPN11 mutation for good prognosis, while abnormal JAK family often indicates poor prognosis. In T-ALL, mutation of NOTCH1 and/or FBXW7 indicates good prognosis.

Additional file 1: Table S1. Demographic data, follow-up time, and ALL subtypes. (DOCX 52 kb)
Additional file 2: Table S2. 112 genes covered by a custom targeted NGS gene panel. (DOCX 94 kb)
Additional file 3: Supplementary: materials and methods. (DOCX 73 kb)
Additional file 4: Supplementary: statistical analysis. (DOCX 52 kb)
Additional file 5: Figure S1. Percentage of ALL patients with different somatic mutations. (TIF 1433 kb)
Additional file 6: Figure S2. Frequency of gene mutations in T-ALL (A), in B-ALL (B), in Ph^B-ALL (C), and in Ph-B-ALL (D). (DOCX 4000 kb)
Additional file 7: Table S3. Signal pathways affected and their frequency. (DOCX 70 kb)

Abbreviations

ALL: Acute lymphoblastic leukemia; CR: Complete remission; NGS: Next-generation sequencing; OS: Overall survival; PCR: Polymerase chain reaction; RFS: Relapse-free survival; SNP: Single nucleotide polymorphisms; WBC: White blood cell

Acknowledgements

The authors thank Drs. Tian Yuan and Qi Zhang of MD Anderson Cancer Center for their valuable suggestions.

Funding

This study was supported by the National Science & Technology Pillar Program (Grant no. 2014BAI09B12), Tianjin Major Research Program of Application Foundation and Advanced Technology (15JCZDJC36400), and Science and technology project of Tianjin (15SZXLCSY00010).

Availability of data and materials

Not applicable. All data used for conclusions are presented in the manuscript and figures.

Authors' contributions

YM and JW were responsible for the conception and design of the study. JF, YL, YJ, and XD participated in the development of methodology of the study. JF, YL, YJ, QF, XG, QL, XZ, KL, ZT, and KT contributed to the acquisition of data (acquired and managed patients’ samples, provided facilities, etc.). JF, YL, KR, YJ, QF, XD, YJ, YW, and DL cooperated with the analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis). JF, YL, YM, JW, MW, and HW wrote, reviewed, and/or revised the manuscript. KR, QL, YJ, and XD contributed to administrative, technical, or material support (i.e., reporting or organizing data, constructing databases). YM supervised the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study design was approved by Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences. The reference number is KZ2015001-EC-1.

Author details

1Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, People’s Republic of China. 2State Key Laboratory of Experimental Hematology, Tianjin 300020, People’s Republic of China.

Received: 25 January 2017 Accepted: 23 February 2017

Published online: 28 February 2017

References

1. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–64.
2. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IKAROS. Nature. 2008;453:1110–4.
3. Fransecky L, Neumann M, Heesch S, Schle C, Ortiz-Tanchere J, et al. Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL. J Hematol Oncol. 2016;9(1):95.
4. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–9.

5. Xu N, Li YL, Li X, Zhou X, Cao R, et al. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2016;9:40.

6. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12:344–57.

7. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.

8. Neumann M, Voisberg S, Schlee C, Heesch S, Schwartz S, Gökbüget N, et al. Mutational spectrum of adult T-ALL. Oncotarget. 2015;6:2754–66.

9. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.